Business
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026 First clinical trial globally targeting B7H3 with a systemic radiopharmaceuticalTwo additional preclinical Radiopharm Ventures’ assets show early positive results with plans to m
About this update from Radiopharm Theranostics Limited
[{"type":"image","alt":"Radiopharm Theranostics","displaySize":"","headline":null,"caption":"Radiopharm Theranostics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqMiWwV7mR9zCwiMw6XzSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b","width":300,"height":110}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026 ","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Two additional preclinical Radiopharm Ventures’ assets show early positive results with plans to move to final candidate selection in 2026 ","length":138,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":539,"olType":false},{"type":"text","content":"SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center (MDACC), from 75% to 87.5%.","length":467,"tagName":"p"},{"type":"text","content":"Radiopharm’s decision to increase the ownership percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets.","length":244,"tagName":"p"},{"type":"text","content":"B7H3 is an immune checkpoint protein that is very infrequently seen in healthy cells but is consistently overexpress...